AJANTPHARM Aktienübersicht
Ajanta Pharma Limited, ein Unternehmen für pharmazeutische Spezialformulierungen, entwickelt, produziert und vermarktet zusammen mit seinen Tochtergesellschaften spezielle pharmazeutische Fertigpackungen.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Belohnungen
Risikoanalyse
Ajanta Pharma Limited Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,412.75 |
| 52 Week High | ₹2,540.00 |
| 52 Week Low | ₹1,386.60 |
| Beta | 0.034 |
| 1 Month Change | 0.74% |
| 3 Month Change | 15.88% |
| 1 Year Change | 63.58% |
| 3 Year Change | 85.01% |
| 5 Year Change | 271.44% |
| Change since IPO | 15,304.90% |
Aktuelle Nachrichten und Updates
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Recent updates
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend
Dec 13Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?
Dec 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting
Nov 19Aktionärsrenditen
| AJANTPHARM | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 1.2% | 0.5% | 2.3% |
| 1Y | 63.6% | 53.0% | 45.0% |
Rendite im Vergleich zur Industrie: AJANTPHARM übertraf die Branche Indian Pharmaceuticals, die im vergangenen Jahr eine Rendite von 59 erzielte.
Preisvolatilität
| AJANTPHARM volatility | |
|---|---|
| AJANTPHARM Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.3% |
Stabiler Aktienkurs: AJANTPHARM hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.
Volatilität im Zeitverlauf: AJANTPHARMDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1973 | 7,713 | Yogesh Agrawal | www.ajantapharma.com |
Ajanta Pharma Limited, ein Unternehmen für pharmazeutische Spezialformulierungen, entwickelt, produziert und vermarktet zusammen mit seinen Tochtergesellschaften spezielle pharmazeutische Fertigpräparate. Das Unternehmen vermarktet und bedient verschiedene therapeutische Segmente wie Malariamittel, Kardiologie, Ophthalmologie, Dermatologie, Schmerztherapie, Gastroenterologie, Antihistaminika, Atemwegserkrankungen und Diabetes. Es bietet auch Tabletten, Kapseln, Pulver, Flüssigkeit, Gelee, Salben, sterile Augentropfen, pharmazeutische Wirkstoffe.
Ajanta Pharma Limited's Grundlagenzusammenfassung
| AJANTPHARM grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹299.51b |
| Gewinn(TTM) | ₹8.16b |
| Umsatz(TTM) | ₹42.09b |
37.2x
Kurs-Gewinn-Verhältnis7.2x
Kurs-Umsatz-VerhältnisIst AJANTPHARM zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| AJANTPHARM Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹42.09b |
| Kosten der Einnahmen | ₹10.67b |
| Bruttogewinn | ₹31.42b |
| Sonstige Ausgaben | ₹23.26b |
| Umsatz | ₹8.16b |
Zuletzt gemeldete Gewinne
Mar 31, 2024
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 64.82 |
| Bruttomarge | 74.66% |
| Nettogewinnspanne | 19.39% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich AJANTPHARM auf lange Sicht entwickelt?
Historische Performance und Vergleiche